• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Potential  adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research

A True Hematologic Emergency
​BY GREGORY TAYLOR, DO, & JACKLYN M​CPARLANE, DO​A 33-year-old woman with a past medical history of sickle cell SS presented to the emergency department with chest pain, difficulty breathing, and a cough for two days. Her chest pain was diffuse, without radiation, and partially reproducible. Her cough was nonproductive, and she also reported fever and chills.The patient noted this was different from her normal back and leg pain from past sickle cell crises. She was following up with a sickle cell specialist, and was compliant with her hydroxyurea treatment.Her temperature was 102.8°F, blood pressure was 94/60 mm...
Source: The Case Files - June 26, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research

New Paradigms in Sepsis: From Prevention to Protection of Failing Microcirculation.
This article is protected by copyright. All rights reserved. PMID: 26190521 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 18, 2015 Category: Hematology Authors: Hawiger J, Veach RA, Zienkiewicz J Tags: J Thromb Haemost Source Type: research

New Paradigms in Sepsis: From Prevention to Protection of Failing Microcirculation
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - July 1, 2015 Category: Hematology Authors: J. Hawiger, R. A Veach, J. Zienkiewicz Tags: Review Article Source Type: research